Demographics and clinical characteristics
| Variables . | n = 25, n (%) . |
|---|---|
| Age (y), mean (SD, range) | 72 (4.9, 62-81) |
| Gender | |
| Male | 17 (68.0) |
| Female | 8 (32.0) |
| Race | |
| White | 23 (92.0) |
| Black or African American | 1 (4.0) |
| Prefer not to say | 1 (4.0) |
| Ethnicity | |
| Not Hispanic or Latino | 24 (96.0) |
| Prefer not to say | 1 (4.0) |
| Marital status | |
| Married | 16 (64.0) |
| Divorced or widowed | 4 (16.0) |
| Single | 5 (20.0) |
| Education | |
| High school or below | 4 (16.0) |
| At least some college | 6 (24.0) |
| College graduate | 5 (20.0) |
| Postgraduate level | 9 (36.0) |
| Prefer not to say | 1 (4.0) |
| Living arrangement | |
| Partner (spouse/significant other) | 18 (72.0) |
| Alone | 7 (28.0) |
| Karnofsky performance status | |
| 90-100 | 4 (16.0) |
| 70-80 | 15 (60.0) |
| 50-60 | 6 (24.0) |
| Diagnosis | |
| AML | 15 (60.0) |
| MDS | 8 (32.0) |
| MDS/MPN overlap | 1 (4.0) |
| Chronic neutrophilic leukemia | 1 (4.0) |
| AML risk group, n=15 | |
| Low | 2 (13.3) |
| Intermediate | 5 (33.3) |
| Adverse | 8 (53.3) |
| MDS risk group, n=8 | |
| Low | 4 (50.0) |
| Intermediate | 3 (37.5) |
| Very high | 1 (12.5) |
| Treatment | |
| HMA combination treatment (e.g., venetoclax) | 11 (44.0) |
| HMA only | 11 (44.0) |
| Other | 3 (12) |
| Chemotherapy cycle at initiation of intervention, n=24* | |
| 1 | 3 (12.5) |
| 2 | 13 (54.2) |
| 3 | 4 (16.7) |
| ≥4 | 4 (16.7) |
| Variables . | n = 25, n (%) . |
|---|---|
| Age (y), mean (SD, range) | 72 (4.9, 62-81) |
| Gender | |
| Male | 17 (68.0) |
| Female | 8 (32.0) |
| Race | |
| White | 23 (92.0) |
| Black or African American | 1 (4.0) |
| Prefer not to say | 1 (4.0) |
| Ethnicity | |
| Not Hispanic or Latino | 24 (96.0) |
| Prefer not to say | 1 (4.0) |
| Marital status | |
| Married | 16 (64.0) |
| Divorced or widowed | 4 (16.0) |
| Single | 5 (20.0) |
| Education | |
| High school or below | 4 (16.0) |
| At least some college | 6 (24.0) |
| College graduate | 5 (20.0) |
| Postgraduate level | 9 (36.0) |
| Prefer not to say | 1 (4.0) |
| Living arrangement | |
| Partner (spouse/significant other) | 18 (72.0) |
| Alone | 7 (28.0) |
| Karnofsky performance status | |
| 90-100 | 4 (16.0) |
| 70-80 | 15 (60.0) |
| 50-60 | 6 (24.0) |
| Diagnosis | |
| AML | 15 (60.0) |
| MDS | 8 (32.0) |
| MDS/MPN overlap | 1 (4.0) |
| Chronic neutrophilic leukemia | 1 (4.0) |
| AML risk group, n=15 | |
| Low | 2 (13.3) |
| Intermediate | 5 (33.3) |
| Adverse | 8 (53.3) |
| MDS risk group, n=8 | |
| Low | 4 (50.0) |
| Intermediate | 3 (37.5) |
| Very high | 1 (12.5) |
| Treatment | |
| HMA combination treatment (e.g., venetoclax) | 11 (44.0) |
| HMA only | 11 (44.0) |
| Other | 3 (12) |
| Chemotherapy cycle at initiation of intervention, n=24* | |
| 1 | 3 (12.5) |
| 2 | 13 (54.2) |
| 3 | 4 (16.7) |
| ≥4 | 4 (16.7) |
HMA, hypomethylating agent.
HMA was planned but switched to hydroxyurea following enrollment.